- Report
- May 2025
- 150 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- March 2025
- 150 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- April 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- April 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- April 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Drug Pipelines
- April 2025
- 180 Pages
Global
From €2197EUR$2,500USD£1,895GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1757EUR$2,000USD£1,516GBP
- Report
- June 2025
- 67 Pages
Global
From €3500EUR$4,267USD£3,125GBP
- Report
- August 2024
- 150 Pages
Global
From €2451EUR$2,789USD£2,114GBP
- Report
- November 2023
- 276 Pages
Global
From €8347EUR$9,500USD£7,200GBP
- Report
- September 2023
- 112 Pages
Global
From €3471EUR$3,950USD£2,994GBP
- Report
- January 2022
- 125 Pages
Global
From €2197EUR$2,500USD£1,895GBP
- Report
- October 2023
- 73 Pages
United States
From €2614EUR$2,975USD£2,255GBP
€3075EUR$3,500USD£2,653GBP
- Report
- November 2023
- 200 Pages
Global
€4389EUR$4,995USD£3,786GBP
- Book
- July 2023
- 320 Pages
The Her2 Receptor is a protein found on the surface of some breast cancer cells. It is a target for drugs used to treat breast cancer. Her2-positive breast cancer is a type of breast cancer that has a higher number of Her2 receptors than normal. Drugs that target the Her2 receptor are used to treat this type of cancer. These drugs work by blocking the activity of the Her2 receptor, which can slow or stop the growth of cancer cells.
Her2-targeted drugs are a key part of the treatment of Her2-positive breast cancer. These drugs can be used alone or in combination with other treatments, such as chemotherapy or hormone therapy. Her2-targeted drugs can be used to treat early-stage and advanced-stage breast cancer.
Some companies in the Her2 Receptor market include Roche, Novartis, AstraZeneca, Pfizer, and Merck. Show Less Read more
